ランキング価格はじめての方へ
  1. 米国企業
  2. C4 Therapeutics, Inc.

C4 Therapeutics, Inc.CCCC

時価総額
$4億
PER
サマリーテーブルに戻る
損益計算書バランスシートキャッシュフロー
2020年
12月31日		2021年
12月31日		2022年
12月31日		2023年
12月31日
Net loss-66-84-128-132
Stock-based compensation expense3223027
Depreciation and amortization2122
Reduction in carrying amount of right-of-use asset1166
Accretion of (premium) discount on marketable securities0-2-14
Amortization of Debt Discount (Premium)0110
Accounts receivable-01-410
Prepaid expenses and other current and long-term assets36-0-3
Accounts payable0-1-30
Accrued expenses and other current liabilities3451
Operating lease liability-1-1-1-5
Deferred revenue-12-25-234
Loss on early extinguishment of debt----1
Other---0
Accounts receivable-01-410
Prepaid expenses and other current and long-term assets36-0-3
Accounts payable0-1-30
Accrued expenses and other current liabilities3451
Operating lease liability-1-1-1-5
Deferred revenue-12-25-234
Net cash used in operating activities-67-87-106-107
Proceeds from maturities of marketable securities104350283290
Purchase of marketable securities294538220130
Purchases of property and equipment1152
Net cash provided by investing activities-191-18958158
Proceeds From Issuance Of Follow On Offering-169--
Proceeds from Issuance of Common Stock---58
Proceeds from Stock Options Exercised1210
Payment of long-term debt − related party---13
Payment of initial public offering costs40--
Proceeds from Stock Options Exercised1210
Other--000
Payments for repurchase of common stock for tax withholding0--0
Net cash provided by financing activities349171145
Other--000
Net cash provided by financing activities349171145
Net change in cash, cash equivalents and restricted cash---4697
Cash paid for interest - related party1121
Deferred revenue in accounts receivable---10
Cash paid for interest - related party1121
Income Taxes Paid0--1
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability-2044-
Capital Expenditures Incurred but Not yet Paid--00
Capital Expenditures Incurred but Not yet Paid--00
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability-2044-
Deferred revenue in accounts receivable---10